• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[严重脓毒症中外源性活化蛋白C]

[Exogenous activated protein C in severe sepsis].

作者信息

Mamontova O A, Protsenko D N, Eliutin D V, Kirienko P N, Gel'fand B R

出版信息

Anesteziol Reanimatol. 2005 May-Jun(3):42-5.

PMID:16076046
Abstract

Exogenous activated protein C combines a marked anti-inflammatory effect on the vascular endothelium and anticoagulative and profibrinolytic activities. The total results of this action are better multiple organ microcirculation and, as a result, elimination and even prevention of irreversible changes in the vitally important organs. The many-sidedness and potency of this effect make the agent essential for intensive therapy of severe sepsis of various etiology. The Russian cooperative study of the efficacy of the exogenous activated protein C--drotrecogine alpha (activated)--has shown that its inclusion into therapy for sepsis with multiple organ dysfunction and septic shock results in longer estimated survival. With this, the best results are observed when therapy is initiated within 48 hours since the development of multiple organ deficiency.

摘要

外源性活化蛋白C对血管内皮具有显著的抗炎作用,并兼具抗凝和促纤溶活性。这一作用的总体结果是改善多器官微循环,从而消除甚至预防重要器官的不可逆变化。这种作用的多面性和强效性使该药物成为各种病因所致严重脓毒症强化治疗的关键药物。俄罗斯对外源性活化蛋白C(重组人活化蛋白C)疗效的合作研究表明,将其用于伴有多器官功能障碍和感染性休克的脓毒症治疗可延长预计生存期。在此情况下,自多器官功能不全发生起48小时内开始治疗时观察到的效果最佳。

相似文献

1
[Exogenous activated protein C in severe sepsis].[严重脓毒症中外源性活化蛋白C]
Anesteziol Reanimatol. 2005 May-Jun(3):42-5.
2
Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.严重脓毒症和脓毒性休克患者输注重组人活化蛋白C(rhAPC)期间的全身和器官功能障碍反应。
Minerva Anestesiol. 2005 Dec;71(12):785-801.
3
Activated protein C for the treatment of severe sepsis.活化蛋白C治疗严重脓毒症
Clin Microbiol Infect. 2009 Apr;15(4):319-24. doi: 10.1111/j.1469-0691.2009.02751.x.
4
Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.活化蛋白C:再审视。更多针对严重脓毒症的临床试验:大多为阴性结果。
Prescrire Int. 2007 Feb;16(87):7-9.
5
Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.急诊科早期目标导向治疗、皮质类固醇及重组人活化蛋白C治疗严重脓毒症和脓毒性休克
Acad Emerg Med. 2006 Jan;13(1):109-13. doi: 10.1197/j.aem.2005.08.005. Epub 2005 Dec 19.
6
[Activated protein C (the impact of PROWESS trial)].[活化蛋白C(PROWESS试验的影响)]
Nihon Rinsho. 2004 Dec;62(12):2296-300.
7
Recombinant human activated protein C for severe sepsis in a neonate.重组人活化蛋白C用于新生儿严重脓毒症
Med Sci Monit. 2002 Nov;8(11):CS90-4.
8
Recombinant activated protein C in pediatric sepsis.重组活化蛋白C用于儿童脓毒症
Pediatr Infect Dis J. 2003 Aug;22(8):743-5. doi: 10.1097/01.inf.0000079362.16086.0c.
9
Use of activated protein C in liver transplantation patients with septic shock.活化蛋白C在感染性休克肝移植患者中的应用。
Liver Transpl. 2008 Nov;14(11):1598-602. doi: 10.1002/lt.21589.
10
Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.血浆白细胞介素-6浓度升高和急性生理与慢性健康状况评分系统II(APACHE II)评分升高可预测严重脓毒症患者发生急性肾损伤。
Clin J Am Soc Nephrol. 2007 Jan;2(1):22-30. doi: 10.2215/CJN.02510706. Epub 2006 Dec 13.